Cessatech A/S Logo

Cessatech A/S

Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.

CESSA | SPGR

Overview

Corporate Details

ISIN(s):
DK0061411964
LEI:
549300WO5SKVXWPOXR16
Country:
Denmark
Address:
Kanonbådsvej 2, 1437 København K
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cessatech A/S is a pharmaceutical company specializing in the development and commercialization of evidence-based medicines for children. The company focuses on addressing unmet needs in pediatric care, particularly the treatment of acute pain. Its lead asset, CT001, is a non-invasive analgesic nasal spray for children aged 1-17 undergoing painful medical procedures. This product is designed as an alternative to traditional pain management solutions, such as intravenous injections, which can be distressing for young patients. Originating as a spinout project from Rigshospitalet, Cessatech's business model centers on developing drugs with a potentially shortened time-to-market. The management team has a proven track record in drug development, paediatric research, and global product launches.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cessatech A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cessatech A/S

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cessatech A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.